We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B.
- Authors
Tatton, W; Chalmers-Redman, R; Tatton, N
- Abstract
Deprenyl and other propargylamines are clinically beneficial in Parkinson's disease (PD). The benefits were thought to depend on monoamine oxidase B (MAO-B) inhibition. A large body of research has now shown that the propargylamines increase neuronal survival independently of MAO-B inhibition by interfering with apoptosis signaling pathways. The propargylamines bind to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The GAPDH binding is associated with decreased synthesis of pro-apoptotic proteins like BAX, c-JUN and GAPDH but increased synthesis of anti-apoptotic proteins like BCL-2, Cu-Zn superoxide dismutase and heat shock protein 70. Anti-apoptotic propargylamines that do not inhibit MAO-B are now in PD clinical trial.
- Publication
Journal of neural transmission (Vienna, Austria : 1996), 2003, Vol 110, Issue 5, p509
- ISSN
0300-9564
- Publication type
Journal Article
- DOI
10.1007/s00702-002-0827-z